February 22, 2021February 22, 2021
Xpovio Open to Advanced Myeloma Patients Outside US via Access Program
News
People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. ... Read more
February 19, 2021February 19, 2021
C4 Therapeutics Readying to Open Phase 1/2a Trial of CFT7455
News
C4 Therapeutics is preparing to launch a clinical trial testing its lead investigational therapy CFT7455 in multiple myeloma and other ... Read more
February 17, 2021February 17, 2021
Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse
News
People with blood type O are significantly less likely to develop multiple myeloma, but those who do are likely to ... Read more
February 15, 2021February 15, 2021
Darzalex Combos Linked to Stronger Cancer Eradication, Prolonged Survival
News
Adding Darzalex (daratumumab) to standard regimens for adults with relapsed or refractory multiple myeloma resulted in higher rates of deep ... Read more
February 12, 2021February 12, 2021
Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients
News
The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people ... Read more
February 10, 2021February 10, 2021
FDA Clears Way for Clinical Trial of HDP-101
News
Heidelberg Pharma has been cleared in the U.S. to begin a clinical trial testing its investigational therapy HDP-101 for the ... Read more
February 8, 2021February 8, 2021
Under-the-skin Velcade Found to Work Better in Farydak Triple Combo
News
Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety ... Read more
February 5, 2021February 5, 2021
Phase 3 Trial of ATG-010 (Xpovio) for Advanced Myeloma Opens in China
News
China’s regulatory agency has approved the start of a Phase 3 clinical trial testing ATG-010 (selinexor), in combination with Velcade ... Read more
February 3, 2021February 3, 2021
EMA Plans Speedy Review of Cilta-cel, CAR T-cell Therapy for Advanced Myeloma
News
An accelerated review will be given an application for European Union approval of ciltacabtagene autoleucel (cilta-cel), a potential CAR T-cell therapy ... Read more
February 1, 2021February 1, 2021
EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients
News
A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to ... Read more
January 29, 2021January 29, 2021
Dosing Begins in Phase 1 Trial of CERC-007
News
Cerecor has dosed the first patient in a Phase 1b clinical trial evaluating CERC-007 as a potential treatment for relapsed ... Read more
January 27, 2021January 27, 2021
Jakafi Plus Steroid Continuing to Treat Multiple Myeloma in Phase 1 Trial
News
Combining the corticosteroid methylprednisolone and Jakafi (ruxolitinib), an approved oral therapy for bone marrow disorders, is showing promising effectiveness in heavily ... Read more

February 22, 2021February 22, 2021

Xpovio Open to Advanced Myeloma Patients Outside US via Access Program

News

People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. through a managed access program. This program, also known as ... Read more

February 19, 2021February 19, 2021

C4 Therapeutics Readying to Open Phase 1/2a Trial of CFT7455

News

C4 Therapeutics is preparing to launch a clinical trial testing its lead investigational therapy CFT7455 in multiple myeloma and other blood cancers. The U.S. Food and Drug Administration (FDA) approved ... Read more

February 17, 2021February 17, 2021

Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse

News

People with blood type O are significantly less likely to develop multiple myeloma, but those who do are likely to have more aggressive disease and poorer survival outcomes, a study ... Read more

February 15, 2021February 15, 2021

Darzalex Combos Linked to Stronger Cancer Eradication, Prolonged Survival

News

Adding Darzalex (daratumumab) to standard regimens for adults with relapsed or refractory multiple myeloma resulted in higher rates of deep and durable responses, according to exploratory analyses of two Phase ... Read more

February 12, 2021February 12, 2021

Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients

News

The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people with multiple myeloma who have received three or more prior ... Read more

February 10, 2021February 10, 2021

FDA Clears Way for Clinical Trial of HDP-101

News

Heidelberg Pharma has been cleared in the U.S. to begin a clinical trial testing its investigational therapy HDP-101 for the treatment of multiple myeloma. The U.S. Food and Drug Administration ... Read more

February 8, 2021February 8, 2021

Under-the-skin Velcade Found to Work Better in Farydak Triple Combo

News

Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people with relapsed or refractory (resistant) multiple myeloma ... Read more

February 5, 2021February 5, 2021

Phase 3 Trial of ATG-010 (Xpovio) for Advanced Myeloma Opens in China

News

China’s regulatory agency has approved the start of a Phase 3 clinical trial testing ATG-010 (selinexor), in combination with Velcade (bortezomib) and dexamethasone, in multiple myeloma patients after one to three ... Read more

February 3, 2021February 3, 2021

EMA Plans Speedy Review of Cilta-cel, CAR T-cell Therapy for Advanced Myeloma

News

An accelerated review will be given an application for European Union approval of ciltacabtagene autoleucel (cilta-cel), a potential CAR T-cell therapy for heavily pre-treated multiple myeloma patients, its developer, Janssen, announced. An accelerated ... Read more

February 1, 2021February 1, 2021

EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients

News

A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to treat adults with relapsed or refractory multiple myeloma who received at ... Read more